Clinical Trial: Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagula
Brief Summary: The purpose of this study is to see if ART-123 (recombinant human soluble thrombomodulin) decreases the number of people who die as a result of Disseminated Intravascular Coagulation (DIC) complication of sepsis.
Detailed Summary:
Sponsor: Artisan Pharma, Inc.
Current Primary Outcome: 28-Day All-cause mortality [ Time Frame: 28 day ]
Original Primary Outcome: 28-Day All-cause mortality
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Artisan Pharma, Inc.
Dates:
Date Received: June 15, 2007
Date Started: July 2007
Date Completion:
Last Updated: May 13, 2011
Last Verified: May 2011